New scan could sharpen ovarian cancer detection

NCT ID NCT05903807

Terminated Diagnosis Sponsor: Aalborg University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new radioactive tracer called FAPI-46, used with a PET/CT scan, can more accurately detect the spread of ovarian cancer compared to standard scans. Researchers planned to enroll 50 women with newly diagnosed ovarian cancer, but the study was terminated early. If the tracer proves effective, it could help doctors stage the cancer more precisely and tailor treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPI-46 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a more accurate way to stage ovarian cancer, helping doctors choose the best treatment plan.
What could go wrong: This is a small, early-phase study that was terminated, so results are limited. The tracer may not prove more accurate than existing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Aalborg University Hospital

Aalborg, North Denmark, 9000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.